Skip Navigation



JAC Advance Access published online on December 19, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm488
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
61/2/460    most recent
dkm488v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thamlikitkul, V.
Right arrow Articles by Trakulsomboon, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thamlikitkul, V.
Right arrow Articles by Trakulsomboon, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

In vitro activity of ceftobiprole against Burkholderia pseudomallei

Visanu Thamlikitkul* and Suwanna Trakulsomboon

Division of Infectious Disease and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

* Corresponding author. Tel/Fax: +66-2-412-5994; E-mail: sivth@mahidol.ac.th

Key Words: B. pseudomallei , melioidosis , cephalosporins

The first 10% of the full text of this article appears below.

Sir,

Burkholderia pseudomallei, a Gram-negative bacterium, causes a disease called melioidosis in humans and animals.1 The bacterium is a soil organism found mainly in Southeast Asia and Northern Australia. Antibiotics currently recommended for therapy of melioidosis are ceftazidime, imipenem, meropenem, amoxicillin/clavulanate, trimethoprim/sulfamethoxazole, doxycycline and chloramphenicol.1 A development of resistance of . . . [Full Text of this Article]

Funding

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?